R&D expense · 2015–2025
Anaptysbio R&D expense
$136M−17.0% · FY2025
Anaptysbio (ANAB) reported $136M in R&D expense for fiscal 2025, −17.0% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $136M | −17.0% | Open → |
| FY20242024-12-31 | $164M | +23.9% | Open → |
| FY20232023-12-31 | $132M | +49.0% | Open → |
| FY20222022-12-31 | $88.8M | −9.8% | Open → |
| FY20212021-12-31 | $98.5M | +23.1% | Open → |
| FY20202020-12-31 | $80.0M | −19.4% | Open → |
| FY20192019-12-31 | $99.3M | +76.8% | Open → |
| FY20182018-12-31 | $56.2M | +90.9% | Open → |
| FY20172017-12-31 | $29.4M | +91.0% | Open → |
| FY20162016-12-31 | $15.4M | −10.9% | Open → |
| FY20152015-12-31 | $17.3M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +22.9%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Anaptysbio R&D expense |url=https://companiesranked.com/en/company/anaptysbio/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Anaptysbio R&D expense. CompaniesRanked. https://companiesranked.com/en/company/anaptysbio/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-anaptysbio-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Anaptysbio R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/anaptysbio/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-088290 · March 3, 2026
{{cite web |title=Anaptysbio R&D expense — 10-K (0001193125-26-088290) |url=https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/anab-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.